Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Completed · Phase 2
Conditions studied: Epidermolysis Bullosa, Epidermolysis Bullosa Simplex
In brief
The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.
Key facts
- Study ID
- NCT03389308
- Run by
- Castle Creek Pharmaceuticals, LLC
- People needed
- 51
- Starts
- 2017-12-01
- Expected to finish
- 2020-04-17
- Last updated by the study team
- 2020-09-16
Who can join
Age: 1 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ann and Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
- University of North Carolina (UNC) - Chapel Hill — Chapel Hill, North Carolina, United States
- Children's Hospital of San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.